Abecma, Breyanzi, I-CARYKTI, UKymriah, UTecartus, Yeskarta
I-CAR T Cell Therapy Esekelwe Kubantu: Ukuphumelela kanye Nezinselele
Isingeniso Esizindeni se-oncology, i-immunotherapy isivele njengendlela yokuqala, esebenzisa amasosha omzimba ukuze alwe nezimila eziyingozi. Kunezindlela eziningi ze-immunotherapeutic, kepha i-Chimeric Antigen Rece.
I-Brexucabtagene autoleucel, iyuniyani yase-Europe, EGiliyadi, I-Kite, UTecartus
I-Tecartus inikeze igunya lokumaketha laseYurophu lokwelashwa kwe-leukemia ebuyele emuva noma e-refractory acute lymphoblastic leukemia.
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..
IBHOLA, I-Brexucabtagene autoleucel, IKite Pharma, UTecartus, ZUMA-3
I-Brexucabtagene autoleucel igunyazwe yi-FDA ngokubuyela emuva noma i-refractory B-cell precursor acute lymphoblastic leukemia
Okthoba 2021: I-Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) igunyazwe i-Food and Drug Administration ezigulini ezikhulile ezine-B-cell precursor acute lymphoblastic leukemia (YONKE). Nge..
I-Acalabrutunib, I-Avelumab, Ukwelashwa kwenqola, Dabrafanib, UKymriah, Izidakamizwa zakamuva, I-Midostaurin, I-Niraparib, I-Pembrolizumab, UTecartus, Unyusibhabha, I-Trametinib, USFDA
Izidakamizwa zakamuva ekwelapheni umdlavuza
Julayi 2021: Hlola izidakamizwa zakamuva ekwelapheni umdlavuza. Minyaka yonke, ngemva kokuhlola izivivinyo nezinye izici ezibalulekile, i-USFDA ivuma izidakamizwa, futhi ngaleyo ndlela iziguli ezinomdlavuza manje zingakholwa ukuthi ikhambi seliseduze kakhulu. ..